Upstream Bio

Yahoo Finance • 2 days ago

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

– Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric receptor complexes – – Data sup... Full story

Yahoo Finance • 23 days ago

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Ra... Full story

Yahoo Finance • 30 days ago

Upstream Bio Reports Positive Top-line Results From Phase 2 VIBRANT Study

(RTTNews) - Upstream Bio, Inc. (UPB) Tuesday announced positive top-line results from Phase 2 VIBRANT study evaluating verekitug in people with chronic rhinosinusitis with nasal polyps. The study met its primary goal showing statistically... Full story

Yahoo Finance • 30 days ago

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted endoscopic nasal polyp score (NPS)... Full story

Yahoo Finance • last month

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will... Full story

Yahoo Finance • 2 months ago

The Math Shows SCHA Can Go To $31

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 2 months ago

Upstream Bio, Inc. reports Q2 results

* Upstream Bio, Inc. press release [https://seekingalpha.com/pr/20190646-upstream-bio-reports-second-quarter-2025-financial-results-and-highlights-continued-progress] (NASDAQ:UPB [https://seekingalpha.com/symbol/UPB]): Q2 Revenue of $0.9... Full story

Yahoo Finance • 3 months ago

Upstream Bio begins phase 2 COPD trial for verekitug

WALTHAM, Mass. - Upstream Bio, Inc. (NASDAQ:UPB) has dosed the first patient in its Phase 2 clinical trial evaluating verekitug for chronic obstructive pulmonary disease (COPD), the company announced Tuesday. The clinical-stage biotech com... Full story

Yahoo Finance • 3 months ago

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for verekitug into third indication, strengthe... Full story

Yahoo Finance • 4 months ago

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

“ Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to tezepelumab “ “ Supports potentially differentia... Full story

Yahoo Finance • 4 months ago

Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced an upcom... Full story

Yahoo Finance • 4 months ago

Upstream Bio Appoints Stacy Price as Chief Technology Officer

WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appoi... Full story

Yahoo Finance • 7 months ago

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 – – Completed upsized IPO with gross proceeds of approximately $293... Full story